laropiprant inn drug used combination niacin reduce blood cholesterol ldl vldl longer sold due increases sideeffects cardiovascular benefit laropiprant cholesterol lowering effect reduces facial flushes induced niacin merck co planned market combination trade names cordaptive us tredaptive europe brands contained mg niacin mg laropiprant niacin cholesterol lowering doses mg per day causes facial flushes stimulating biosynthesis prostaglandin especially skin dilates blood vessels via activation prostaglandin receptor subtype increasing blood flow thus leading laropiprant acts selective receptor antagonist inhibit vasodilation prostaglandin activation taking mg aspirin minutes prior taking niacin also proven prevent flushing patients presumably suppressing prostaglandin medication also increases risk gastrointestinal though increased risk less trial patients patients stopped taking medication combination drug group versus niacin april us food drug administration fda issued approved letter tredaptive approved european medicines agency ema july january merck co inc announced withdrawing drug worldwide result european regulators heart protection study hdl reduce incidence vascular events involved adults treatment group received g extendedrelease niacin mg laropiprant daily study results reported july showed combination niacin laropiprant beneficial effects compared placebo treatment increase adverse httpsenwikipediaorgwikilaropiprant